Tempol as a potential protective agent for nucleoside reverse transcriptase inhibitor (NRTI)-induced mitochondrial toxicity

被引：0
|
作者：
Liu, Yongmin [1 ]
Liu, Yongmin [1 ]
Phuonggiang Nguyen [1 ]
Gibbons, Alexander [1 ]
Mitchell, James B. [2 ]
Poirier, Miriam C. [1 ]
机构：
[1] NCI, Carcinogen DNA Interact Sect, NIH, Bethesda, MD 20892 USA
[2] NCI, LCBG & Tumor Biol Sect, RBB, NIH, Bethesda, MD 20892 USA
来源：
MITOCHONDRION | 2012年 / 12卷 / 05期
关键词：
D O I：
10.1016/j.mito.2012.07.021
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
22
引用
收藏
页码：557 / 558
页数：2
相关论文
共 50 条
  • [41] Emtricitabine: A novel nucleoside reverse transcriptase inhibitor
    Molina, JM
    Cox, SL
    DRUGS OF TODAY, 2005, 41 (04) : 241 - 252
  • [42] Abacavir: A new nucleoside reverse transcriptase inhibitor
    Osborne, NG
    JOURNAL OF GYNECOLOGIC SURGERY, 1998, 14 (04) : 199 - 200
  • [43] Discovery of an innovative stereoselective synthesis of BMS-986001: A nucleoside reverse transcriptase inhibitor (NRTI) for the treatment of HIV infection
    Ortiz, Adrian
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [44] Mitochondrial DNA Depletion in Rat Liver Induced by Fosalvudine Tidoxil, a Novel Nucleoside Reverse Transcriptase Inhibitor Prodrug
    Venhoff, Ana C.
    Lebrecht, Dirk
    Reuss, Frank U.
    Heckl-Oestreicher, Brigitte
    Wehr, Roland
    Walker, Ulrich A.
    Venhoff, Nils
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (07) : 2748 - 2751
  • [45] Investigation of mitochondrial toxicity of nucleoside reverse transcriptase inhibitors in a newly developed in ovo model
    Moreno, Inmaculada Garcia
    Wiertz, Martina
    Hoeschele, Doris
    TOXICOLOGY LETTERS, 2007, 172 : S78 - S78
  • [46] Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor use in the DAWNING study
    Brown, Dannae
    Kaplan, Richard
    Losso, Marcelo
    Brites, Carlos
    Wang, Ruolan
    Underwood, Mark
    Hopking, Judy
    Aboud, Michael
    Sievers, Jorg
    ANTIVIRAL THERAPY, 2022, 27 (01)
  • [47] Nucleoside reverse transcriptase inhibitor effects on adipocyte mitochondrial DNA quantity and quality in vitro
    Lim, HGW
    Sedwell, R
    Duarte, N
    Cooper, DA
    Kelleher, A
    Carr, A
    Mallon, PWG
    ANTIVIRAL THERAPY, 2005, 10 (08) : L41 - L42
  • [48] Apricitabine. Anti-HIV agent, nucleoside reverse transcriptase inhibitor.
    Revill, P.
    Serradell, N.
    DRUGS OF THE FUTURE, 2006, 31 (12) : 1035 - 1041
  • [49] Low rates of nucleoside reverse transcriptase inhibitor and nonnucleoside reverse transcriptase inhibitor drug resistance in Botswana
    Moyo, Sikhulile
    Gaseitsiwe, Simani
    Zahralban-Steele, Melissa
    Maruapula, Dorcas
    Nkhisang, Tapiwa
    Mokaleng, Baitshepi
    Mohammed, Terence
    Ditlhako, Tsotlhe R.
    Bareng, Ontlametse T.
    Mokgethi, Thatayaone P.
    van Widenfelt, Erik
    Pretorius-Holme, Molly
    Mine, Madisa O.
    Raizes, Elliot
    Yankinda, Etienne Kadima
    Wirth, Kathleen E.
    Gaolathe, Tendani
    Makhema, Joseph M.
    Lockman, Shahin
    Essex, Max
    Novitsky, Vlad
    AIDS, 2019, 33 (06) : 1073 - 1082
  • [50] Contribution of nucleoside-analogue reverse-transcriptase inhibitor therapy tolipoatrophy in HIV infected patients: a model of drug-induced mitochondrial toxicity
    不详
    MITOCHONDRION, 2004, 4 (01) : 70 - 71
12345